NasdaqCM:MDXGBiotechs
MiMedx Group (MDXG) Q1 Loss And Margin Compression Test Bullish Growth Narratives
MiMedx Group (MDXG) opened 2026 with Q1 revenue of US$59.0 million and a basic EPS loss of US$0.07, compared with revenue of US$88.2 million and basic EPS of US$0.05 in Q1 2025. Over the past year, the company has seen trailing twelve month revenue move from US$348.9 million in Q4 2024 to US$389.4 million in Q1 2026, while trailing basic EPS shifted from US$0.29 to US$0.21. This puts the latest quarterly loss against a backdrop of positive earnings over the last four reported quarters as...